Why wooo ashtool?
RECENT HIGHLIGHTS
$3.7 million cash burn
- Record quarter for ADAPT sales which continue to accelerate.
- Net cash outflows reduced by 23% over the previous quarter (excluding the R&D rebate).
- Quarterly underlying sales1 are up 16% on the prior quarter.
- Two separate patent applications for TAVR technologies were filed in the
US.
- A new funding facility was arranged for up to $10.0M in secured debt from Partners for Growth (after quarter close).
- Entered into an exclusive supply agreement for TMVR with 4C Medical.
- CardioCel® 3D moved from a pre-market programme to an expanded
access programme.
- The new Royal Adelaide Hospital (nRAH) officially opened on
5 September 2017 – poised to positively impact infusion business sales.
Ann: Appendix 4C - quarterly, page-3
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.50 |
Change
0.210(0.99%) |
Mkt cap ! $413.0M | |||
| Open | High | Low | Value | Volume |
| $21.50 | $21.50 | $21.00 | $247.6K | 11.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $21.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 244 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.21 |
Change
0.210 ( 0.09 %) |
||||
| Open | High | Low | Volume | ||
| $21.19 | $21.21 | $21.19 | 143 | ||
| Last updated 14.24pm 06/05/2024 ? | |||||
| AVR (ASX) Chart |